• Dextran Sulfate Sodium Salt in Colitis Research

  2026-10-09

  Dextran sulfate sodium salt, including DSS (MW 35000-45000), is widely used as a chemical injury model for studying intestinal inflammation and mucosal repair. This overview separates supplier descriptions from peer-reviewed evidence, examines how DSS can frame questions about epithelial barrier failure, and discusses a 2026 Cell Death & Disease study reporting a GPR35-KLF5 repair circuit linked to tryptophan metabolism. It also defines the model’s boundaries: chemical epithelial injury is not equivalent to human ulcerative colitis, and mechanistic findings require independent replication and quantitative validation.

• Romidepsin (FK228): HDAC Biology & HCC Evidence

  2026-10-09

  Romidepsin, also called FK228, is a class I HDAC inhibitor used to study epigenetic modulation, cell-cycle arrest, and apoptosis. Recent hepatocellular carcinoma research links HDAC2-dependent SmD2 regulation to alternative splicing and PARP-inhibitor sensitivity, but the combination evidence remains preclinical.

• CD36 Lipid Signaling and Immune Escape in AML

  2026-10-08

  Guo et al. show that CD36 supports acute myeloid leukemia immune escape through a non-canonical lipid-sensing pathway in which oxidized LDL and palmitate jointly activate innate immune signaling, rather than simply fueling lipid oxidation. The study also reports that high-fat conditions and decitabine can intensify this immunosuppressive program, while statin-mediated pathway targeting improved decitabine responses in the reported models.

• Cleavage-Resistant TREM2 and Macrophage Efferocytosis

  2026-10-08

  Dong et al. engineered a cleavage-resistant TREM2 receptor that preserves DAP12-linked signaling when inflammatory ADAM17 activity would otherwise impair macrophage efferocytosis. In mouse models of metabolic-dysfunction-associated steatohepatitis and atherosclerosis, phosphatidylserine-functionalized lipid nanoparticles delivered CRT mRNA in situ and reduced apoptotic-cell accumulation and inflammation, while leaving important translational questions unresolved.

• Central Opioid Control of Mechanical Hypersensitivity

  2026-10-07

  Yin et al. (2024) identify a lateral parabrachial-to-hypothalamic-to-spinal circuit that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study separates mechanical pain outcomes from better-established thermal effects and provides convergent circuit evidence for spinal gate-control disruption as a central mechanism.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-10-07

  Satir and colleagues examined whether partial BACE inhibition could reduce amyloid-beta secretion without impairing synaptic transmission. In cultured rat cortical neurons, reductions below 50% were not associated with detectable synaptic dysfunction, whereas stronger inhibition reduced both amyloid-beta secretion and synaptic transmission, supporting a cautious exposure-response interpretation rather than a simple all-or-none model.

• PLGA Nano-Adjuvant and Mucosal Immunity in Chicks

  2026-10-06

  A 2026 Poultry Science study evaluated PEI-LSP-RA-PLGA, a layered PLGA-based nano-adjuvant designed to combine sustained release, intestinal targeting, and immune regulation in chicks receiving an inactivated H9N2 vaccine. The reported increases in serum IgG and intestinal IgA, together with chemokine-receptor and immune-pathway findings, support the platform as a promising research model, although its protective value, safety, and broader applicability require further validation.

• Oltipraz: Nrf2, MASLD, and Evidence Boundaries

  2026-10-06

  Oltipraz is a dithiolethione described as an Nrf2-pathway activator and inducer of phase II detoxification enzymes. Its product-level rationale is relevant to chemoprevention research, but evidence from a 2026 Qushi Huoxue ointment mouse study should not be treated as direct evidence for Oltipraz in MASLD.

• CFTRinh-172: Reading CFTR Trafficking Data

  2026-10-05

  CFTRinh-172 is a selective CFTR inhibitor that can provide a functional counterpoint to plasma-membrane trafficking measurements. This article explains how to interpret channel activity, surface abundance, and cell-context effects without confusing pharmacological inhibition with restoration of CFTR biology.

• Oltipraz and Nrf2: MASLD Research Context

  2026-10-05

  Oltipraz is a supplier-described Nrf2 pathway activator and phase II enzyme inducer with a research history in chemoprevention. A 2026 mouse study of Qushi Huoxue ointment links Nrf2-associated signaling, autophagy, and ferroptosis suppression in MASLD, but its findings do not establish that Oltipraz itself treats MASLD or reproduce the effects of a complex botanical formula.

• CHIR-99021: From Wnt Control to 3D Translation

  2026-10-04

  CHIR-99021, also known as CT99021, is best understood not merely as a GSK-3 inhibitor but as a tool for testing how pathway state shapes cell identity within increasingly complex human models. This article connects its established signaling rationale with findings from a vascularized neuron–microglia co-culture study, while separating direct evidence from translational hypotheses.

• Anti-ROR1 Antibody: Evidence Boundaries

  2026-10-03

  Anti-ROR1 Antibody (Zilovertamab) offers a focused way to examine ROR1 target engagement, while a recent DON hepatotoxicity study illustrates how mechanistic evidence should be interpreted. This article distinguishes binding, pathway modulation, and disease-level inference without overstating cross-domain relevance.

• Pifithrin-α for p53 Mechanism Studies

  2026-10-02

  Pifithrin-α (PFTα) is a practical p53 inhibitor for separating p53-driven transcriptional effects from downstream ferroptotic injury, apoptosis, and radiation responses. This guide converts a developmental neurotoxicity study into executable HT-22 workflows, controls, optimization strategies, and interpretation safeguards.

• S-Adenosylhomocysteine in Neural Methylation Assays

  2026-10-01

  S-Adenosylhomocysteine (SAH) enables controlled methyltransferase inhibition and SAM/SAH ratio modulation in cell-based experiments. This guide translates radiation-induced neural differentiation findings into practical SAH workflows, controls, and troubleshooting strategies without confusing a proposed metabolic perturbation with a mechanism established by the reference study.

• CD36 Lipid Signaling and Immune Escape in AML

  2026-10-01

  Guo et al. identify a non-canonical CD36 program in AML in which oxidized LDL and palmitate cooperate to activate innate immune signaling and suppress T-cell activity. The study also shows that lipid restriction with statins can improve decitabine efficacy, while highlighting why metabolic context matters when interpreting immunotherapy resistance.

7383 records 1/493 page Next 12345 下5页 Last page